WALTHAM, Mass., March 25, 2021 (Globe NEWSWIRE) — EyeGate Prescribed drugs, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a scientific-stage company developing and commercializing goods
WALTHAM, Mass., March 25, 2021 (Globe NEWSWIRE) — EyeGate Prescribed drugs, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a scientific-stage company developing and commercializing goods